ArticleCancers2023
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review.
Islam Eljilany, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J Lee, Megan Othus, James Moon, John M Kirkwood, Vernon K Sondak, Antoni Ribas and 2 more
Open access · goldAbstract read
In one paragraphArticle in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 13 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 6 institutions in 1 country.
Islam EljilanyHouston Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Arish NoorHouston Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Mahati ParavathaneniHouston Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Ibrahim YassineHouston Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Sandra J LeeDana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Megan OthusFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
James MoonFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Vernon K SondakHouston Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Antoni RibasDepartment of Psychology, College of Life Sciences, University of California, Los Angeles, CA 90095, USA.
Kenneth F GrossmannMerck and Co., Kenilworth, NJ 07033, USA.
Ahmad A TarhiniHouston Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Moffitt Cancer Center · USFred Hutch Cancer Center · USUniversity of California, Los Angeles · USHarvard University · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USUPMC Hillman Cancer Center · US
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MSWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6MTherapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MNCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer CenterUG1CA233184 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ADAM M BRUFSKY, John Munn Kirkwood · 2019 to 2026
$7.7MNCI NIH HHS P01 CA244118NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA121973NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180820NCI NIH HHS U10CA180820, U10180794, U10CA180888, UG1CA233180, UG1CA23318, 1UG1CA189974, U10CA180888, U10CA1808194NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233184
6 · The paper itselfAbstract
backgroundTreatment with immune checkpoint inhibitors (ICIs) has been linked to granulomatous and sarcoid-like lesions (GSLs) affecting different organs. This study sought to evaluate GSL incidence in patients with high-risk melanoma treated with cytotoxic T-lymphocyte antigen 4 (CTLA4) or programmed cell death 1 (PD1) blockade adjuvant therapy in two clinical trials: ECOG-ACRIN E1609 and SWOG S1404. Descriptions and GSL severity ratings were recorded.
methodsData were collected from ECOG-ACRIN E1609 and SWOG S1404. Descriptive statistics along with GSL severity grades were reported. Additionally, a literature review for such cases was summarized.
resultsA total of 11 GSL cases were reported among 2878 patients treated with either ICI or with High-Dose Interferon Alfa-2b (HDI) in ECOG-ACRIN E1609 and SWOG S1404 trials. Cases were numerically more commonly reported with ipi10, followed by pembrolizumab, ipi3, and HDI, respectively. Most of the cases were grade III. Further, organs involved included lung, mediastinal lymph nodes, skin and subcutaneous tissue, and eye. Furthermore, a summary of 62 reports in the literature was described.
conclusionsGSLs following anti-CTLA4 and anti-PD1 antibody therapy in patients with melanoma were reported unusually. Reported cases ranged in grade from I to III and appeared manageable. Careful attention to these events and their reporting will be essential to better guide practice and management guidelines.
Indexed as
adjuvant melanomagranulomatous lesionsinterferonipilimumabpembrolizumabsarcoid-like lesions
Identifiers
PMID37174027
PMCPMC10177189
OpenAlexW4367843732
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390